Signild Åsberg
@SignildAsberg
Followers
68
Following
42
Statuses
35
Stroke physician and researcher. Member of the steering committee, the Swedish Stroke Register
Uppsala, Sverige
Joined August 2014
RT @ESOstroke: WSO & ESO joint webinar on uncovering key insights from the World Stroke Congress 2024. 📑 📅 20 Novem…
0
13
0
RT @WorldStrokeEd: #WSC2024 Following the #Optimas results, Dr. @SignildAsberg presented the much-anticipated #CATALYST IPD meta-analysis…
0
36
0
RT @OPTIMAS_UCL: Don't miss the presentation of the OPTIMAS and CATALYST results this week at #WSC2024, which will be featured in Day 2's p…
0
10
0
RT @StrokeAHA_ASA: David G. Sherman Lecture by @warach_steven: A shift toward selection and evaluation of #stroke patients for therapies ba…
0
13
0
RT @OPTIMAS_UCL: Congratulations to @BoNorrving who received the @ESOstroke Honorary Award this year for his incredible work in stroke care…
0
1
0
RT @OPTIMAS_UCL: @SignildAsberg earlier gave us a comprehensive overview of registry-based RCTs! #ESOC2024
0
1
0
RT @ESOstroke: Discussing biomarkers, rhythm control and anticoagulation in an interactive set up with lively participation. Thank you @m…
0
6
0
RT @OPTIMAS_UCL: The new 2023 National Clinical Guideline ( has a recommendation for patients with moderate/severe…
0
7
0
@DavidSeiffge @BoNorrving Thank you David, TIMING is the first RRCT in the stroke field demonstrating NOAC to be safe also in the acute phase of ischemic stroke w AF. Still, further evidence is needed and I can’t wait to see result from our collaboration with @OPTIMAS, @ELAN and START (@warach_steven)
0
0
1
RT @WorldStrokeEd: #TIMING Early vs delayed #NOAC start after acute ischemic stroke 🧠💊🩸 @BoNorrving 👏 Presented at #ESOC2021, now you ca…
0
13
0
@syaddana_neuro Subgroups findings in Fig 6 should be interpreted cautiously, but the actual proportion of pts with NIHSS≥15 was 9% (early) and 8% (delayed). NIHSS was 4 (median) and 6 (mean) in both groups.
0
0
2
@MicieliA_MD @syaddana_neuro In the nation-wide pragmatic TIMING study, there were no inclusion/exclusion criteria based on NIHSS. Still, NIHSS was 4 (median) in both the early and the delayed group, as compared to 3 in the general Swedish stroke population with AF & NOAC.
0
0
0
RT @DavidSeiffge: Very important trial on timing of DOAC therapy in patients with stroke and AF. Intriguing to see ischemic event rates in…
0
12
0
RT @MelindaRoaldsen: It has been a privilege to work and collaborate with so many wonderful stroke scientists across Europe&New Zealand🧠💫It…
0
4
0
RT @warach_steven: Here at #ISC22. Getting ready to present the CERTAIN Collaboration’s large study showing a significant reduction in symp…
0
7
0
RT @StrokeAHA_ASA: #BloggingStroke contributor Vignan Yogendrakumar @VYogendrakumar discusses highlights from the Closing Ceremony and Larg…
0
1
0
RT @ESOstroke: Now live at #ESOC2021➡️ Prof. Signild Åsberg & Prof. Jonas Oldgren presenting the results of the TIMING #stroke #clinicaltr…
0
6
0